Table 2.
Pharmacokinetic parameters of QTP in plasma and observed adverse side effects following IM administration of three NSPs (F1–F3) to beagle dogs (35 mg kg−1 as QTP).
| Formulations | F1 | F2 | F3 | |
|---|---|---|---|---|
| Pharmacokinetic parameters a ) | T max [h] | 2 | 24 | 24 |
| C max [h] | 2770.0 ± 637.9*** | 644.5 ± 107.2** | 249.8 ± 99.9 | |
| T 1/2 [h] | 56.7 ± 14.2** | 22.3 ± 5.7*** | 105.4 ± 11.3 | |
| AUC0–35 days [ng h mL−1] | 34067.6 ± 3868.8# | 39153.8 ± 4845.8# | 37255.0 ± 5559.5 | |
|
AUC0–∞ [ng h mL−1] |
34163.7 ± 3867.4# | 39309.4 ± 4915.2# | 37454.2 ± 5521.2 | |
| Adverse side effects b ) | Limping | + (3/4) | + (1/4) | – |
| Vomiting | – | + (1/4) | – | |
a)
Data are expressed as mean ± standard deviation (n = 4). Significant difference analyzed by unpaired two‐tailed Student's t‐test compared with F3: ** p < 0.01; *** p < 0.001; #no significant difference (p > 0.05);
b)
Adverse side effect was observed (+) with frequency provided in parentheses, or no adverse side effects were observed (–).